Elevated soluble IL-7 receptor concentration in non-survivor ICU patients
- 305 Downloads
Patients admitted to intensive care units (ICU) are prone to immunosuppression, the intensity and duration of which are associated with deleterious outcomes . Currently, therapy such as IL-7 is being tested (NCT02640807) with the intention of restoring immune functions. In this context, and to follow up on a previous study in septic shock patients published in Intensive Care Medicine , we further investigated the prognostic value of the soluble form of IL-7 receptor alpha chain (or sCD127) in ICU patients. We confirmed and extended our previous results to ICU patients with systemic inflammatory response syndrome, presenting with various severity levels.
To this end, we measured sCD127 plasmatic concentration with a standardized and robust ELISA assay (Method 1 in the electronic supplementary material), in a cohort of 734 ICU patients . This study was approved by our ethical institutional review board (IRB#5044). Clinical data are described in Tables 1 and 2 of...
KeywordsIntensive Care Unit Patient Septic Shock Patient sCD127 Level Ethical Institutional Review Board Receptor Alpha Chain
The authors gratefully acknowledge the MIP-Réa study group for their participation in the MIP-Réa clinical study. The authors also would like to thank Hélène Vallin, Nathalie Panel, Marion Provent, and Sylvie De La Salle for their great help in patients’ inclusion and Anne Portier for the clinical samples management. The authors thank Caroline Le Gall from Methodomics for statistical analysis. Funding was provided by the authors’ institutions (Hospices Civils de Lyon and bioMérieux) and was part of ADNA (Advanced Diagnostic for New Therapeutic Approaches), a program dedicated to personalized medicine, coordinated by Institut Mérieux and supported by the French public agency BPI France.
Compliance with ethical standards
Conflicts of interest
All authors work in a joint research unit, co-funded by the Hospices Civils de Lyon and bioMérieux. FV, GM, and AL are co-inventors in two patents families covering soluble CD127 biomarkers. This does not alter the authors’ adherence to all the Intensive Care Medicine policies on sharing data and materials.
- 3.Friggeri A, Cazalis M-A, Pachot A et al (2016) Decreased CX3CR1 messenger RNA expression is an independent molecular biomarker of early and late mortality in critically ill patients. Crit Care 20:204Google Scholar